INCYTE
Incyte Biosciences International Sàrl, a European subsidiary of Incyte Corporation, and GENESIS Pharma S.A., a leading Greek pharmaceutical company, today announced that Incyte has granted GENESIS Pharma exclusive rights to commercialize Iclusig® (ponatinib) in Greece. Under the terms of the agreement, GENESIS Pharma will be responsible for sales and marketing, medical affairs, and regulatory and reimbursement support for Iclusig in Greece.
“The agreement with GENESIS Pharma will expand the availability of Iclusig to patients in geographies beyond our current European footprint,” said Jonathan Dickinson, Incyte’s General Manager, Europe. “We look forward to collaborating with GENESIS Pharma, whose oncology and hematology experience makes them an ideal partner to enable patient and physician access to Iclusig in Greece.”
In Europe and other select ex-U.S. countries, Iclusig is approved for the treatment of adult patients with chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to specific second generation tyrosine kinase inhibitor (TKIs); or who have the T315I mutation.
“We are very happy to announce our partnership with Incyte. For us, it is another step forward to delivering our mission to provide innovative hematology treatments to patients in Greece,” said Constantinos Evripides, Chief Executive Officer of GENESIS Pharma. “Once available, Iclusig will add to the broad portfolio of treatments for patients with rare and difficult to treat hematological diseases that GENESIS Pharma commercializes in Greece. We are very pleased to have another leading international pharmaceutical company, like Incyte, recognize our expertise and high quality standards, and place its trust in us.”
According to the European Medicines Agency’s orphan drug designation1 and the HAEMACARE project2 , there are approximately 1,000 CML and Ph+ ALL patients in Greece.
GENESIS Pharma has submitted a pricing application for Iclusig in Greece; the application is currently under review by the Greek Ministry of Health. Pending their approval, the commercial launch of Iclusig is expected to occur in the first half of 2017.
About Iclusig ® (ponatinib) tablets
Iclusig targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, including the T315I mutation, which has been associated with resistance to other approved TKIs.
In the EU, Iclusig is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation, or for the treatment of adult patients with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
Incyte has an exclusive license from ARIAD Pharmaceuticals, Inc. to develop and commercialize Iclusig in the European Union and 28 other countries, including Switzerland, Norway, Iceland, Turkey, Israel and Russia.
Iclusig® is a registered trademark of ARIAD Pharmaceuticals, Inc.
About Incyte
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. Headquartered in Wilmington, Delaware, Incyte also has offices in Switzerland and nine other European countries. For additional information on Incyte, please visit the Company’s website at www.incyte.com .
Follow @Incyte on Twitter at https://twitter.com/Incyte .
About GENESIS Pharma
GENESIS Pharma was among the first pharmaceutical companies in Europe specialized in biopharmaceutical products and is currently the largest among Greek companies specializing in branded innovative medicines, mainly in the therapeutic areas of Oncology, Hematology, CNS, Gastroenterology and Nephrology. The company has created a strong product portfolio that includes high-tech pharmaceutical products for severe and rare diseases, through long standing strategic alliances for the broader region of Southeast Europe with some of the leading multinational pharmaceutical companies committed to cutting edge R&D.
For further information please visit www.genesispharma.com .
Incyte Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: whether the collaboration with GENESIS Pharma will be successful in expanding access for patients in Greece to Iclusig; whether the Greek Ministry of Health will approve the pricing application for Iclusig; and the expected timing of the commercial launch of Iclusig in Greece. These forward-looking statements are based on the Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including risks detailed from time to time in the Incyte’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended September 30, 2016. The Company disclaims any intent or obligation to update these forward-looking statements.
1 Public summary of opinion on orphan designation, Committee for Orphan Medicinal Products, European Medicines Agency, 2 March 2010, http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2010/03/WC500075158.pdf
2 Sant et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010 116:3724-3734
View source version on businesswire.com: http://www.businesswire.com/news/home/20161108005603/en/
Contact:
Incyte Contacts
Media
Catalina Loveman
+1
302-498-6171
cloveman@incyte.com
or
Investors
Michael
Booth, DPhil
+1 302-498-5914
mbooth@incyte.com
or
GENESIS
Pharma Contact
Vicky Karra
Corporate Affairs Manager
+30
210 87 71 500
vkarra@genesispharma.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA202515.6.2025 09:15:00 CEST | Press release
Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell productionIn high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved a complete or partial hematologic responsewith the majority (82%) realizing a complete responseA reduction in peripheral blood mutCALR variant allele frequency (VAF) was observed in 89% of evaluable patients correlating with hematologic responseInitial results demonstrate a favorable safety profile – no dose limiting toxicities were reported, a maximum tolerated dose was not reached and 98% of patients remained on treatmentIncyte will host an in-person analyst and investor event highlighting this data at EHA today, Sunday, June 15, 2025, from 6:00 - 7:30 a.m. EDT (12:00 -1:30 p.m. CEST) Incyte (Nasdaq:INCY) today announced the first
Perma-Pipe International Holdings, Inc. Announces First Quarter Fiscal 2025 Financial Results13.6.2025 15:14:00 CEST | Press release
The Company generated net sales of $46.7 million compared to $34.3 million in the first quarter of 2024Income before income taxes of $7.4 million versus $2.6 million in the first quarter of 2024Backlog of $131.1 million at April 30, 2025, compared to $63.1 million at April 30, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the first quarter ended April 30, 2025. “Sales for the first quarter were $46.7 million, resulting in an increase of $12.4 million, or 36.2%, compared to $34.3 million in the same quarter last year. Net income attributable to common stock of $5.0 million was an increase of $3.6 million, or 243%, compared to $1.4 million in the first quarter of the prior year,” noted President and CEO Saleh Sagr. Backlog currently stands at $131.1 million, a decrease of $7.0 million, compared to $138.1 million at January 31, 2025. However, the Company has experienced a significant increase in backlog of $68.0 million, or 108%, compare
Capcom’s Devil May Cry 5 Sales Top 10 Million Units!13.6.2025 15:00:00 CEST | Press release
– Capcom further enhances global brand awareness with its Single Content Multiple Usage strategy – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide cumulative sales of Devil May Cry 5 havesurpassed 10 million units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613788747/en/ Devil May Cry 5 logo In Devil May Cry 5, players can enjoy thrilling, high-speed gameplay, stylish action, and beautiful graphics, depicted with intricate realism thanks to Capcom’s proprietary RE ENGINE. The title has garnered strong support from users due to its exceptional gameplay experience, leading to expanded sales as a catalog title since its release. Capcom provided an even more advanced story and action elements in the game with the addition of a new playable character, and more recently, on April 3, 2025, the company released the new Devil May Cry animated series on Netflix, in line with the company’s Single Content Multiple Us
realme Summer Party: a Major Event and an Exclusive Collaboration with TikTok13.6.2025 14:59:00 CEST | Press release
realme, one of the world's leading smartphone brands, held a summer festival on June 6 and 7 at the foot of the Eiffel Tower with fun activities. Visitors could try their hand at ring throwing, immortalize their moments at the Photobooth van, or leave with exclusive gifts. Each participant received a voucher to exchange for a prize in the dedicated area for a successful festive experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612984325/en/ Live photo from realme Summer Party and the newly launched GT 7 Dream Edition A festive event at the foot of the Eiffel Tower The event was a great success, thanks to the engagement of participants on-site and through social media. Many visitors shared photos and videos, creating a dynamic and friendly atmosphere, amplified by the realme community. An exclusive collaboration between realme and TikTok This collaboration between realme and TikTok extends beyond this event. Indee
Take It Slow: Why Ireland Is the Perfect Destination for the ‘Unrushed’ Traveller13.6.2025 14:30:00 CEST | Press release
Tourism Ireland--In a world that’s always rushing, Ireland is extending a gentle invitation: take your time. With its winding coastal trails, soul-soothing landscapes, and deep-rooted traditions, Ireland is emerging as one of Europe’s most natural fits for slow tourism — a growing global travel trend focused on deeper, more meaningful experiences over fast-paced itineraries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612345730/en/ Cycling on greenway, County Waterford From misty mornings in the Burren to long afternoons along the Wild Atlantic Way, Ireland rewards those who slow down. Whether it’s connecting with local craftspeople, foraging along the coast, lingering over storytelling sessions in a pub, or staying in family-run farmhouses — the country’s charm reveals itself not in a rush, but in the details. What is ‘Slow Tourism’? Slow tourism encourages travellers to engage more fully with a destination, spending
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom